DANBURY, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq:
BIOD) today announced that it will issue its fourth quarter and fiscal year
2007 financial results on December 11, 2007. Following the issuance of its
financial results, Biodel's senior management team will host a conference
call to discuss the results.
December 11, 2007 Schedule:
After the market closes Q4 and fiscal year 2007 results will be
distributed by PR Newswire
4:20 p.m. EST To participate in the conference call, dial:
1-877-718-5104 (United States) or
4:30 p.m. EST Conference call begins
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay 14 days following the event.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.
|SOURCE Biodel Inc.|
Copyright©2007 PR Newswire.
All rights reserved